Ayahuasca: The Vine of the Soul and the Amazon’s Gift

The old man has not eaten meat in three weeks. He has not had sex in longer. He has not consumed salt, sugar, alcohol, or spicy food. He has bathed in the river every morning before dawn and spent the afternoons in a small hut, alone, singing songs that no one taught him — songs he says the plants gave him directly, in dreams and in ceremony, songs that belong to him the way a fingerprint belongs to a finger.

He is an ayahuascero — a healer in the Shipibo-Conibo tradition of the Peruvian Amazon — and tonight he will brew the medicine.

In one hand he holds sections of a thick, woody vine: Banisteriopsis caapi, the “vine of the soul,” which the Shipibo call oni. In the other, he holds leaves from a shrub that grows in the understory: Psychotria viridis, which the Quechua call chacruna. He will pound the vine with a wooden mallet, layer it with the leaves in a large pot, cover it with river water, and boil it for hours — sometimes eight, sometimes twelve, sometimes the entire day — reducing the liquid to a thick, dark, bitter tea.

Neither plant, taken alone in this way, would do much. The vine contains harmala alkaloids — harmine, harmaline, tetrahydroharmine — which produce a mild sedative and slightly psychoactive effect, nothing you’d write a song about. The leaves contain N,N-dimethyltryptamine — DMT — one of the most potent psychoactive molecules known to science, but one that is completely neutralized by an enzyme in the human gut, monoamine oxidase, before it can reach the brain. Eat the leaves by themselves and nothing happens. The enzyme breaks the DMT apart before it can do its work.

But the harmala alkaloids in the vine inhibit that enzyme. They are monoamine oxidase inhibitors — MAOIs. Drink the vine first, or alongside the leaves, and the enzyme that would normally destroy the DMT is temporarily disabled. The DMT passes through the gut intact. It reaches the bloodstream. It crosses the blood-brain barrier. It binds to the 5-HT2A serotonin receptor.

And then the world opens.

This is the pharmacological genius at the heart of ayahuasca. Two plants. Neither works alone. Together, they produce one of the most profound psychoactive experiences available to the human nervous system. To understand what this means, you need to understand the context in which this discovery was made.

The Impossible Discovery

The Amazon rainforest contains approximately 80,000 plant species. Some estimates run higher. It is the most biodiverse terrestrial ecosystem on Earth — a place where a single hectare can hold more tree species than all of North America combined.

Out of this staggering library of botanical possibilities, indigenous Amazonian peoples identified two specific plants, combined them in a specific way, and produced a brew whose mechanism of action — MAOI-facilitated oral DMT activation — was not understood by Western pharmacology until the twentieth century. The harmala alkaloids inhibit a specific enzyme. The DMT requires the inhibition of that specific enzyme to become orally active. This is not folk medicine in the sense of “willow bark tea helps with headaches.” This is targeted pharmacological synergy.

How did they figure it out?

The Western scientific answer is: we don’t know. Trial and error is the usual hand-wave, but the math doesn’t hold. Eighty thousand plant species, tested in pairwise combinations, represents billions of possible experiments. Even if you narrow the field dramatically — by testing only plants that local herbalists had already identified as individually interesting — the combinatorial space is vast. The idea that someone, somewhere, through random experimentation, happened to combine a vine containing MAOIs with a leaf containing DMT, prepared them correctly (boiling for hours is not optional — shorter preparation times produce a weaker brew), and recognized the synergistic result for what it was, strains the explanatory power of accident.

The indigenous answer, given consistently across dozens of Amazonian cultures separated by hundreds of miles and mutually unintelligible languages, is: the plants told us.

This answer makes Western scientists uncomfortable. It should. Not because it’s wrong in any verifiable sense — you cannot disprove a claim about the origin of knowledge by the standards that apply to pharmaceutical discovery — but because no better explanation exists. The “trial and error” hypothesis is not a tested theory. It is a placeholder that allows Western science to avoid engaging with an indigenous knowledge claim it cannot evaluate.

Wade Davis, the ethnobotanist and National Geographic Explorer-in-Residence, has written extensively about this problem. In One River (1996), he describes his years in the Amazon studying Schultes' legacy and concludes that the sophistication of indigenous plant knowledge — not just ayahuasca but thousands of preparations, poisons, medicines, and agricultural techniques — represents an intellectual achievement of the first order, one that Western science has barely begun to appreciate, let alone explain.

Richard Evans Schultes, the Harvard ethnobotanist who spent over a decade living with indigenous Amazonian peoples in the 1940s and 1950s, catalogued hundreds of psychoactive plant preparations. He was a rigorous scientist. He was also honest enough to admit that the question of how indigenous peoples discovered these combinations remained, to him, genuinely mysterious.

The mystery is part of the medicine. Every culture that uses ayahuasca places the plants themselves at the center of the story — not as passive raw materials but as active teachers. The vine teaches. The leaves teach. The brew is a curriculum. Whether this is metaphor, cosmology, or a description of something real that Western epistemology lacks the tools to evaluate is one of the most interesting questions at the intersection of ethnobotany and consciousness research.

The Traditions: Older Than We Can Prove

Archaeological evidence for ayahuasca use is frustratingly thin, because the Amazon is one of the worst environments on Earth for preserving organic material. Tropical heat and humidity devour everything. Wooden artifacts rot. Plant residues decompose. The archaeological record of the Amazon is largely a record of ceramics and stone, and neither ayahuasca plant leaves distinctive chemical signatures on pottery in ways that survive millennia of tropical decay.

What we have instead is ethnographic depth. Ayahuasca use has been documented in over seventy indigenous groups across the western Amazon basin — spanning modern-day Peru, Ecuador, Colombia, Brazil, and Bolivia. These traditions use different names for the brew (ayahuasca in Quechua, yagé or yajé in Tukano, caapi in Tupi, natem in Shuar, oni in Shipibo), different admixture plants alongside or instead of Psychotria viridis (including Diplopterys cabrerana, which also contains DMT, and various other plants that contribute additional alkaloids), and different ceremonial structures. But the core technology — Banisteriopsis caapi vine plus a DMT-containing plant, prepared by extended boiling — is universal across the tradition.

The linguistic and cultural diversity of ayahuasca-using peoples suggests an origin deep enough to predate the divergence of these groups — potentially thousands of years. Some researchers have proposed dates of 3,000 to 5,000 years for the earliest ayahuasca use, based on the cultural distribution and the depth of integration into indigenous cosmologies. Others are more conservative. Nobody places the origin after European contact. This is not something the Spanish taught.

A 2019 discovery provided the first hard archaeological evidence: a ritual bundle excavated from a rock shelter in southwestern Bolivia, radiocarbon-dated to approximately 1,000 CE, contained chemical residues of harmine (from Banisteriopsis caapi), DMT, bufotenine, and cocaine. The bundle — a leather bag containing wooden snuffing tablets, a snuffing tube, and spatulas — belonged to a ritual specialist. It confirmed that complex psychoactive preparations involving multiple plants, including ayahuasca components, were in use in South America at least a thousand years ago. The actual tradition is almost certainly far older.

The Shipibo Way: Icaros, Dieta, and the Architecture of Ceremony

The Shipibo-Conibo of the Ucayali River region in Peru have one of the best-documented ayahuasca traditions, and their ceremonial structure reveals something important about how these traditions work: the ceremony is not the point. The ceremony is the container. The healing is what happens inside the container, and the container takes months to build.

The dieta. Before a ceremony — and especially before the years-long training that makes an ayahuascero — the participant follows a dieta: a set of dietary and behavioral restrictions that varies by tradition and by healer but typically includes abstaining from salt, sugar, pork, red meat, alcohol, sex, and strong spices. The dieta can last days, weeks, or months. During the training of a healer, it can last years.

The dieta is not arbitrary asceticism. In the Shipibo understanding, each restriction has a specific purpose. Salt and sugar “cloud” the plant’s ability to communicate with the person. Sex disperses the energy that the plant is trying to concentrate. Alcohol interferes with the subtle perceptions that ceremony develops. The dieta is preparation in the same way that the Eleusinian fasting was preparation — it tunes the instrument before the concert.

The icaros. The songs. The icaros are the most distinctive element of Shipibo ayahuasca practice, and they are not what Western observers expect.

An icaro is not a pre-composed hymn. It is a song that the healer received from the plants during their own training — given to them during ceremony, in vision, through the direct instruction of the plant spirits. Each ayahuascero has their own repertoire of icaros, accumulated over years of practice and dieta. The songs are considered the primary healing tool — more important than the brew itself. The ayahuasca opens the space. The icaros do the work.

During ceremony, the healer sings icaros throughout the experience — modulating the energy in the room, guiding the visions, directing the medicine toward the source of the patient’s illness, calling in specific plant spirits for specific purposes. Some icaros calm. Some icaros intensify. Some are used to close and protect the space. The healer reads the energy of the room and selects songs accordingly, in real time, for hours.

The Shipibo represent their icaros visually as kené — the intricate geometric patterns that appear in Shipibo textiles, ceramics, and body art. These patterns are not decorative. They are the visual form of the songs. The icaros are sung into the patient; the kené patterns are the shape those songs take in the visionary space. This is synesthetic technology — a healing practice that moves between sound, vision, and somatic experience as if these were dialects of the same language. Which, in the Shipibo understanding, they are.

The ceremony itself. Ayahuasca ceremonies typically begin after nightfall. The space — a maloca (ceremonial house) or an open-air structure — is cleared and protected by the healer through preliminary icaros and the blowing of mapacho (wild tobacco) smoke. Participants sit or lie on mats. The healer prepares the individual doses, sometimes blowing tobacco smoke over each cup and singing a brief icaro to “charge” it.

The participants drink. The healer drinks. Typically twenty to forty minutes pass before the effects begin. And then, for the next four to six hours, the ceremony unfolds.

The Experience: What Happens When the World Opens

Describing an ayahuasca experience is, in the anthropological literature, a bit like describing a color to someone who hasn’t seen it. Every account reaches for metaphor and every metaphor falls short. But the consistent features, reported across thousands of accounts from indigenous practitioners and Western participants alike, are striking in their specificity:

The purge. Vomiting — la purga — is not a side effect. In the indigenous understanding, it is the medicine, or at least the first phase of it. The purging is understood as the physical expulsion of illness, negative energy, emotional blockage, and accumulated spiritual toxicity. Not everyone vomits, but many do, sometimes intensely. Diarrhea can accompany or replace vomiting. Western participants who have been told that the visions are the point often discover, to their surprise, that the purge is what they actually needed — that the body knew what to release before the mind had caught up.

The Shipibo do not treat the purge as an unfortunate prerequisite to the good part. The purge is the good part, or at least an inseparable component of it. The medicine cleans the house before it redecorates.

The visions. Ayahuasca’s visual component is legendary, and distinct from psilocybin or LSD visuals in character. Psilocybin tends toward flowing, organic, interconnected patterns — fractals, spirals, the sense of seeing the hidden geometry of nature. LSD tends toward sharper, more crystalline, sometimes more mechanical imagery. Ayahuasca tends toward narrative. The visions frequently tell stories. They show places. They present beings.

Snakes are ubiquitous — winding through the visions in forms ranging from terrifying to luminous. Jaguars appear frequently. Geometric patterns, often resembling Shipibo kené, are common. Many participants describe the sensation of moving through spaces — underwater realms, forest canopies, cosmic architectures, the interiors of cells, the surface of other planets. The visions are less “patterns you see” and more “places you go.”

Entity contact. The most characteristic and most controversial aspect of the ayahuasca experience is the encounter with what participants consistently describe as autonomous beings — entities that communicate, teach, challenge, heal, and sometimes judge. The specific character varies: people report encounters with plant spirits, ancestors, animal guides, geometric intelligences, maternal presences, and beings that defy categorization.

Whether these entities are “real” — whether they represent contact with non-human intelligences, archetypal structures of the unconscious mind, or pharmacologically generated neural artifacts — is a question that divides even experienced practitioners. The indigenous position is unambiguous: the entities are real. They are the spirits of the plants, the ancestors, the intelligence of the forest. The Western clinical position is carefully agnostic. What is not debatable is the phenomenological consistency: thousands of people, across cultures and centuries, report the same kinds of encounters with the same kinds of beings.

Emotional catharsis. Ayahuasca frequently surfaces repressed or unprocessed emotional material with startling directness. Childhood traumas, unresolved grief, self-deceptions, relationship patterns — the brew has a reputation for showing you precisely the things you have been avoiding, in a way that makes avoidance impossible. The experience can be beautiful. It can also be brutal. The phrase commonly used by Western participants is that ayahuasca “shows you what you need to see, not what you want to see.”

For many participants, the emotional component is the most lasting element of the experience. The visions fade. The catharsis stays. People report that ayahuasca allowed them to forgive, to grieve, to release, to understand — in a single night — emotional material they had spent years failing to process through conventional means.

The duration is typically four to six hours, significantly longer than smoked or vaporized DMT (five to twenty minutes) and comparable to psilocybin. The extended duration is part of the medicine. The experience unfolds in waves — multiple peaks and valleys, often with distinct thematic phases. The healer’s icaros guide these phases, intensifying or calming the experience as needed.

The overall experience is frequently described — by indigenous practitioners and Western participants alike, in surveys and in private — as the most significant experience of their lives.

The Science: What the Researchers Are Finding

Ayahuasca research lags behind psilocybin research in volume but not in significance.

The landmark study came from Fernanda Palhano-Fontes and colleagues in 2019: a randomized, placebo-controlled trial of ayahuasca for treatment-resistant depression, published in Psychological Medicine. Twenty-nine patients who had not responded to at least two conventional antidepressant treatments were given either a single dose of ayahuasca or placebo. At seven days post-treatment, the ayahuasca group showed significantly greater reductions in depression scores. The effect was rapid — improvements were measurable at day one — and clinically meaningful.

This was the first randomized, placebo-controlled trial of ayahuasca for depression, and it confirmed what smaller open-label studies had suggested: ayahuasca has antidepressant properties that are rapid in onset and effective in patients who haven’t responded to conventional treatment.

The pharmacological connection to psilocybin research is direct. DMT and psilocin (the active metabolite of psilocybin) are both tryptamine psychedelics that act primarily on the 5-HT2A serotonin receptor. They are, in molecular terms, close cousins. The therapeutic mechanisms likely overlap: both appear to increase neuroplasticity, disrupt the default mode network (the brain’s autopilot system, associated with rumination and depression), and facilitate emotional processing.

But the differences are significant. Ayahuasca is a whole-plant brew with dozens of alkaloid compounds beyond DMT and the harmala alkaloids. The beta-carbolines in Banisteriopsis caapi have their own pharmacological activity — harmine and harmaline have demonstrated anti-inflammatory, neuroprotective, and antidepressant properties in preclinical studies, independent of their MAO-inhibiting function. The brew is not just DMT plus an enzyme inhibitor. It is a complex pharmacological preparation whose full activity profile is not yet understood.

Additionally, the ceremonial context in which ayahuasca is traditionally consumed — the icaros, the community, the healer’s guidance, the preparation through dieta — may contribute therapeutic effects that a purely pharmacological analysis would miss. Jordi Riba’s research group at the Autonomous University of Barcelona has studied the neuropharmacology of ayahuasca extensively, finding that regular ceremonial ayahuasca use is associated with reduced cortical thinning, improved psychological well-being, and no evidence of cognitive impairment — suggesting that long-term ceremonial use may be neuroprotective rather than neurotoxic.

The evidence base is growing. It is not yet large enough to support the clinical adoption pathway that psilocybin is on. But it is consistent enough to take seriously.

The Modern Retreat Economy: Commerce and Its Costs

Beginning in the 1990s and accelerating dramatically in the 2000s and 2010s, ayahuasca moved from the Amazon to the world.

Iquitos, Peru — a city of half a million people accessible only by river or air, the largest city on Earth not connected to a road network — became the center of the ayahuasca retreat industry. Dozens of retreat centers opened in the surrounding jungle, offering week-long or longer programs that typically include multiple ceremonies, dieta, and integration work. Prices range from a few hundred dollars at basic jungle lodges to several thousand at luxury centers. The retreats attract participants from across the Western world — overwhelmingly white, overwhelmingly middle-class, overwhelmingly seeking relief from depression, addiction, PTSD, existential crisis, or the less clinically defined malaise of modern life.

The industry expanded beyond Iquitos. Costa Rica, the Netherlands, Portugal, Spain, and parts of the United States (where ayahuasca exists in a legal gray zone for some religious organizations, notably the UDV and Santo Daime churches, whose use has been protected by court decisions under the Religious Freedom Restoration Act) now host retreat centers. Ayahuasca tourism has become a global market.

The ethics are complicated and the complications are worth taking seriously.

The appropriation question. Ayahuasca ceremony was developed by indigenous Amazonian peoples over centuries or millennia. The commercialization of that ceremony by Western-owned retreat centers — many of which employ indigenous healers at wages that, while locally significant, represent a fraction of the revenue the centers generate — reproduces the same extractive pattern that marks the Western encounter with Maria Sabina’s velada and with entheogenic traditions globally. The knowledge was taken. The people who developed it benefit unevenly.

Some centers address this directly, operating as indigenous-led enterprises or devoting significant revenue to community development. Others do not. The participant’s responsibility is to ask, before booking, who benefits from the money they spend.

The safety question. The risks of ayahuasca are real and include interactions that can be fatal.

The MAO-inhibiting harmala alkaloids in ayahuasca interact dangerously with a range of substances:

SSRIs and SNRIs (fluoxetine, sertraline, venlafaxine, and others): combining an MAOI with a serotonin reuptake inhibitor can cause serotonin syndrome — a potentially fatal condition characterized by hyperthermia, seizures, and cardiovascular collapse. Multiple deaths have been associated with this interaction. Any reputable retreat center will screen participants for SSRI use and require a washout period. Centers that do not screen are dangerous and should be avoided.

Tyramine-rich foods (aged cheese, cured meats, fermented foods, soy sauce): MAOIs prevent the breakdown of tyramine, which can cause hypertensive crisis. The traditional dieta restrictions — which exclude fermented and preserved foods — are, in addition to their spiritual function, a pharmacological safety protocol that predates the Western understanding of MAO inhibition by centuries.

Other psychoactive substances: The combination of ayahuasca with stimulants, other psychedelics, or MDMA carries unpredictable risks.

The qualification question. Not everyone who calls themselves a shaman is one. The globalization of ayahuasca has created a market for ceremony leaders, and the market has attracted people whose training ranges from decades of traditional apprenticeship to a few weeks at another retreat center. There is no licensing board. There is no quality control. The participant is responsible for vetting the healer’s background, and the information available is often inadequate.

The abuse question. This must be stated directly: sexual abuse by ceremony leaders occurs and has been extensively documented. The ayahuasca experience produces extreme psychological vulnerability. Participants are often physically incapacitated by purging, disoriented by visions, and in an emotional state of complete openness. Predatory individuals in positions of ceremonial authority have exploited this vulnerability, and the cases that have been publicly documented — by journalists including Daniela Peluso and organizations like the Ethnobotanical Stewardship Council — likely represent a fraction of the total.

This is not an indigenous problem. Sexual predation in ceremony settings has been documented among both indigenous and non-indigenous leaders. The vulnerability is structural — it is inherent to the power dynamic of the ceremony itself — and addressing it requires screening, accountability structures, the presence of multiple facilitators, and the willingness of communities to take reports seriously.

Anyone considering an ayahuasca retreat should ask: What is the center’s policy on physical contact during ceremony? Are there multiple facilitators of different genders? What is the reporting mechanism for misconduct? How does the center vet its healers? If these questions are met with vagueness or defensiveness, go somewhere else.

Ayahuasca and Psilocybin: Cousins, Not Twins

For readers whose primary reference point is psilocybin — whether through microdosing, ceremony, or clinical research — ayahuasca shares a pharmacological family tree but occupies a different branch.

The receptor. Both act primarily on the 5-HT2A serotonin receptor. DMT (ayahuasca’s visionary compound) and psilocin (psilocybin’s active metabolite) are both tryptamines that fit the same molecular lock. The subjective experiences share common features: ego dissolution, visual phenomena, emotional catharsis, mystical-type experiences.

The molecule. DMT is not psilocin. The experience profile is different — DMT tends toward more vivid entity encounters, more narrative visual content, and a different emotional texture that participants often describe as “darker” or “deeper” than psilocybin, though both descriptions are imprecise. The purging component of ayahuasca has no parallel in psilocybin use.

The duration. Psilocybin: four to six hours. Ayahuasca: four to six hours. Smoked DMT: five to twenty minutes. The MAO inhibitor in ayahuasca extends DMT’s duration to match psilocybin’s — which is, again, pharmacologically elegant. The indigenous preparation essentially time-releases a molecule that would otherwise be too brief for therapeutic work.

The context. Psilocybin in the clinical setting is administered in a controlled room with trained therapists, eye shades, and curated music. Ayahuasca in the traditional setting is administered in a jungle clearing with a healer singing icaros in the dark. The container is different. The contents overlap but are not identical. Which is “better” is not a meaningful question — they are different medicines for different situations, shaped by different cultures over different timescales.

The research trajectory. Psilocybin is further along the clinical pipeline: breakthrough therapy designation from the FDA, Phase 2 and Phase 3 trials completed, approved as a medicine in Australia. Ayahuasca research is earlier-stage — fewer trials, smaller sample sizes, less regulatory traction. This does not mean ayahuasca is less effective. It means psilocybin is easier to standardize, dose, and regulate, because it is a single synthesizable compound rather than a complex plant brew.

The connection between them is the connection between all tryptamine entheogens: they are different keys to the same lock. The lock is the 5-HT2A receptor. The door it opens — whatever that door opens onto — appears to be the same door that the Vedic priests accessed with Soma, that the Eleusinian initiates accessed with kykeon, that Maria Sabina accessed with los niños santos, and that research participants at Johns Hopkins are accessing with synthetic psilocybin today.

The Gift and the Responsibility

Ayahuasca is not psilocybin in a different bottle. It is a complete technology — pharmacological, ceremonial, ecological, and epistemological — developed over centuries by peoples who understood the forest at a depth that Western science is only beginning to approach.

The pharmacology is extraordinary: a two-plant synergy that achieves targeted enzyme inhibition to activate an otherwise orally inactive compound, discovered without microscopes, without gas chromatography, without any of the tools that Western chemistry considers necessary for pharmaceutical development.

The ceremony is extraordinary: a healing practice built around plant-taught songs, visionary navigation, and a cosmology in which the distinction between healer, patient, plant, and spirit is permeable by design.

The ethics are not extraordinary. They are familiar. A powerful practice developed by indigenous peoples has been discovered by the Western world, extracted from its context, and commercialized. The pattern that began with Wasson in Huautla repeats in Iquitos and every retreat center that markets indigenous knowledge to Western seekers at Western prices. The plants are not the problem. The extraction is the problem. And the extraction is not just pharmaceutical — it is cultural, economic, and spiritual.

The responsibility falls on participants. Know what you are entering. Know who you are paying. Know the risks — pharmacological and human. Know that the tradition you are accessing has living custodians who deserve credit, compensation, and respect. Know that the purge is part of the medicine, that the difficulty is part of the healing, and that the entity you meet in the dark may have something to tell you that you did not want to hear.

The vine has been growing in the Amazon for as long as there have been trees to grow on. It will continue growing after the retreat centers close and the journal articles are published and the last tourist has gone home. What it offers — what it has always offered — is not escape from the human condition. It is confrontation with it. Full, unfiltered, purgative, luminous confrontation with everything you are, delivered in the dark, accompanied by songs, in the most biodiverse place on Earth.

Whether that is a gift depends entirely on what you are willing to receive.

This article is part of Kind Stranger’s Ancient Roots series, exploring the deep history of psychoactive plants and fungi in human civilization. For the story of how psilocybin mushrooms were introduced to the Western world — a parallel story of indigenous knowledge meeting Western curiosity — see Maria Sabina and the Velada. For the ancient mystery of Soma, which may have involved a similar MAOI-plus-psychoactive combination, see The Soma Mystery. For the science of psilocybin — DMT’s tryptamine cousin — see our psilocybin guide.